Skyrizi (risankizumab-rzaa) is a medication used to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, as well as adults with active psoriatic arthritis or moderately-to-severely active Crohn's disease. Skyrizi is not known to interact with alcohol and there is no warning in the drug’s Product Label against drinking alcohol while receiving Skyrizi.

While drinking alcohol isn’t contraindicated while Skyrizi is being used as a treatment, alcohol consumption is known to be higher in people with psoriasis than the general population and drinking alcohol can worsen the symptoms of psoriasis. People with psoriasis may benefit from limiting or avoiding alcohol. Alcohol consumptions should also be limited or avoided in people with Crohn's disease if if causes symptoms to flare up.